Kura Oncology, Inc. (KURA)
| Market Cap | 846.91M +68.1% |
| Revenue (ttm) | 71.64M +5.4% |
| Net Income | -294.57M |
| EPS | -3.35 |
| Shares Out | 88.77M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,680,613 |
| Open | 9.18 |
| Previous Close | 9.05 |
| Day's Range | 9.04 - 9.64 |
| 52-Week Range | 5.45 - 12.49 |
| Beta | 0.36 |
| Analysts | Strong Buy |
| Price Target | 31.17 (+226.73%) |
| Earnings Date | May 12, 2026 |
About KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional n... [Read more]
Financial Performance
In 2025, Kura Oncology's revenue was $67.48 million, an increase of 25.24% compared to the previous year's $53.88 million. Losses were -$278.67 million, 60.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for KURA stock is "Strong Buy." The 12-month stock price target is $31.17, which is an increase of 226.73% from the latest price.
News
Kura Oncology Transcript: Status update
Ziftomenib plus 7+3 in newly diagnosed AML achieved high CR and MRD negativity rates, with durable responses and favorable safety, supporting ongoing phase III trials. The combination may reduce transplant needs and expand market potential, with robust early commercial momentum.
Kura Oncology Press release: Status update
Kura Oncology issued a press release on June 12, 2026, disclosing material business information to investors.
Kura Oncology Slides: Status update
Kura Oncology has posted slides in relation to its latest quarterly earnings report, which was published on June 12, 2026.
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial –
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Transcript: Investor update
Darlifarnib combined with RAS inhibitors shows promising efficacy and manageable safety in KRAS-driven tumors, with particularly strong results in pancreatic cancer. A platform trial will evaluate multiple combinations across tumor types, supporting broad applicability and future registrational studies.
Kura Oncology Press release: Investor update
Kura Oncology issued a press release on June 3, 2026, disclosing material business information to investors.
Kura Oncology Slides: Investor update
Kura Oncology has posted slides in relation to its latest quarterly earnings report, which was published on June 3, 2026.
Kura reports data supporting darlifarnib potential for KRAS-mutant cancers
Kura Oncology (KURA) highlighted new clinical and translational data supporting darlifarnib as a potential foundational combination platform for KRAS-mutant cancers and other targeted therapy settings...
Kura Oncology Highlights Darlifarnib's Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy
– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve...
Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML
– 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once-daily dose – – Central MRD negativity in 75% of CRc responders with ...
Kura Oncology Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
KOMZIFTI's launch in relapsed/refractory NPM1-mutant AML is exceeding expectations, with strong clinical data supporting its use as a combinable backbone. High response rates and robust MRD negativity in AML trials, along with promising results in solid tumors, position the pipeline for significant growth.
Kura Oncology Proxy statement: Proxy filing
Kura Oncology filed a proxy statement on May 26, 2026, providing details for shareholder voting and corporate governance matters.
Kura Oncology reports first-in-human data from the FIT-001 clinical trial
Kura Oncology (KURA) reported compelling first-in-human data from the FIT-001 clinical trial of its next-generation farnesyl transferase inhibitor, or FTI, darlifarnib in combination with adagrasib in...
Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors
– Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients –
Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit
SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA) today announced its participation in the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Kura ma...
Kura Oncology Transcript: Bank of America Global Healthcare Conference 2026
Ziftomenib is showing strong early uptake in relapsed/refractory NPM1 mutant AML, with robust clinical data and broad payer coverage. Darlifarnib is advancing in combination strategies, with new data and strategic updates expected soon.
Kura Oncology reports Q1 EPS (83c), consensus (78c)
Reports Q1 revenue $18.27M, consensus $25.92M. As of March 31, Kura had $580.8M in cash, cash equivalents and short-term investments, compared to $667.2M as of December 31, 2025. The company…
Kura Oncology Earnings Call Transcript: Q1 2026
KOMZIFTI's launch exceeded expectations with $5.8M in Q1 revenue, strong physician adoption, and 40% of patients receiving combination therapy. Phase III programs are ahead of plan, and robust liquidity supports continued growth and multiple upcoming clinical catalysts.
Kura Oncology Earnings release: Q1 2026
Kura Oncology released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Kura Oncology Quarterly report: Q1 2026
Kura Oncology has published its Q1 2026 quarterly earnings report on May 12, 2026.
Kura Oncology Reports First Quarter 2026 Financial Results
– $5.8 million in KOMZIFTI™ (ziftomenib) net product revenue in first full quarter of commercialization – – Robust new patient starts and early launch dynamics, including repeat use, switching and com...
Kura Oncology Slides: Corporate presentation
Kura Oncology has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
Kura, Kyowa Kirin to present updated frontline data from Phase 1 KOMET-007 trial
Kura Oncology, (KURA) and Kyowa Kirin (KYKOF) announced that updated results from the frontline arm of the Phase 1 KOMET-007 clinical trial evaluating ziftomenib in combination with cytarabine plus da...
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
– Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML –